\n \n\n \n \n \n \n \n \n Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.\n \n \n \n \n\n\n \n Nichol, A.; French, C.; Little, L.; Haddad, S.; Presneill, J.; Arabi, Y.; Bailey, M.; Cooper, D J.; Duranteau, J.; Huet, O.; Mak, A.; McArthur, C.; Pettilä, V.; Skrifvars, M.; Vallance, S.; Varma, D.; Wills, J.; and Bellomo, R.\n\n\n \n\n\n\n The Lancet, 386(10012): 2499–2506. December 2015.\n Number: 10012\n\n\n\n
\n\n\n\n \n \n $\"Erythropoietin$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{nichol_erythropoietin_2015,\n\ttitle = {Erythropoietin in traumatic brain injury ({EPO}-{TBI}): a double-blind randomised controlled trial},\n\tvolume = {386},\n\tissn = {01406736},\n\tshorttitle = {Erythropoietin in traumatic brain injury ({EPO}-{TBI})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0140673615003864},\n\tdoi = {10.1016/S0140-6736(15)00386-4},\n\tlanguage = {en},\n\tnumber = {10012},\n\turldate = {2020-08-23},\n\tjournal = {The Lancet},\n\tauthor = {Nichol, Alistair and French, Craig and Little, Lorraine and Haddad, Samir and Presneill, Jeffrey and Arabi, Yaseen and Bailey, Michael and Cooper, D James and Duranteau, Jacques and Huet, Olivier and Mak, Anne and McArthur, Colin and Pettilä, Ville and Skrifvars, Markus and Vallance, Shirley and Varma, Dinesh and Wills, Judy and Bellomo, Rinaldo},\n\tmonth = dec,\n\tyear = {2015},\n\tnote = {Number: 10012},\n\tpages = {2499--2506},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial.\n \n \n \n \n\n\n \n Young, P.; Bailey, M.; Beasley, R.; Henderson, S.; Mackle, D.; McArthur, C.; McGuinness, S.; Mehrtens, J.; Myburgh, J.; Psirides, A.; Reddy, S.; and Bellomo, R.\n\n\n \n\n\n\n JAMA, 314(16): 1701. October 2015.\n Number: 16\n\n\n\n
\n\n\n\n \n \n $\"Effect$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_effect_2015,\n\ttitle = {Effect of a {Buffered} {Crystalloid} {Solution} vs {Saline} on {Acute} {Kidney} {Injury} {Among} {Patients} in the {Intensive} {Care} {Unit}: {The} {SPLIT} {Randomized} {Clinical} {Trial}},\n\tvolume = {314},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of a {Buffered} {Crystalloid} {Solution} vs {Saline} on {Acute} {Kidney} {Injury} {Among} {Patients} in the {Intensive} {Care} {Unit}},\n\turl = {http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.12334},\n\tdoi = {10.1001/jama.2015.12334},\n\tlanguage = {en},\n\tnumber = {16},\n\turldate = {2020-08-23},\n\tjournal = {JAMA},\n\tauthor = {Young, Paul and Bailey, Michael and Beasley, Richard and Henderson, Seton and Mackle, Diane and McArthur, Colin and McGuinness, Shay and Mehrtens, Jan and Myburgh, John and Psirides, Alex and Reddy, Sumeet and Bellomo, Rinaldo},\n\tmonth = oct,\n\tyear = {2015},\n\tnote = {Number: 16},\n\tpages = {1701},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.\n \n \n \n \n\n\n \n Young, P.; Saxena, M.; Bellomo, R.; Freebairn, R.; Hammond, N.; van Haren, F.; Holliday, M.; Henderson, S.; Mackle, D.; McArthur, C.; McGuinness, S.; Myburgh, J.; Weatherall, M.; Webb, S.; and Beasley, R.\n\n\n \n\n\n\n New England Journal of Medicine, 373(23): 2215–2224. December 2015.\n Number: 23\n\n\n\n
\n\n\n\n \n \n $\"Acetaminophen$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_acetaminophen_2015,\n\ttitle = {Acetaminophen for {Fever} in {Critically} {Ill} {Patients} with {Suspected} {Infection}},\n\tvolume = {373},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1508375},\n\tdoi = {10.1056/NEJMoa1508375},\n\tlanguage = {en},\n\tnumber = {23},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Young, Paul and Saxena, Manoj and Bellomo, Rinaldo and Freebairn, Ross and Hammond, Naomi and van Haren, Frank and Holliday, Mark and Henderson, Seton and Mackle, Diane and McArthur, Colin and McGuinness, Shay and Myburgh, John and Weatherall, Mark and Webb, Steve and Beasley, Richard},\n\tmonth = dec,\n\tyear = {2015},\n\tnote = {Number: 23},\n\tpages = {2215--2224},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Venous thromboembolism rates in lower limb immobilization after Achilles tendon injury unchanged after introduction of prophylactic aspirin: audit.\n \n \n \n\n\n \n Braithwaite, I.; Dunbar, L.; Eathorne, A.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Journal of Thrombosis and Haemostasis, 14: n/a–n/a. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{braithwaite_venous_2015,\n\ttitle = {Venous thromboembolism rates in lower limb immobilization after {Achilles} tendon injury unchanged after introduction of prophylactic aspirin: audit},\n\tvolume = {14},\n\tdoi = {10.1111/jth.13224},\n\tjournal = {Journal of Thrombosis and Haemostasis},\n\tauthor = {Braithwaite, Irene and Dunbar, Liam and Eathorne, Allie and Weatherall, Mark and Beasley, Richard},\n\tyear = {2015},\n\tpages = {n/a--n/a},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Using cardiac output monitoring to guide perioperative haemodynamic therapy.\n \n \n \n \n\n\n \n McGuinness, S.; and Parke, R.\n\n\n \n\n\n\n Current Opinion in Critical Care, 21(4). 2015.\n Number: 4\n\n\n\n
\n\n\n\n \n \n $\"Using$ Paper\n \n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{mcguinness_using_2015,\n\ttitle = {Using cardiac output monitoring to guide perioperative haemodynamic therapy},\n\tvolume = {21},\n\tissn = {1070-5295},\n\turl = {https://journals.lww.com/co-criticalcare/Fulltext/2015/08000/Using_cardiac_output_monitoring_to_guide.15.aspx},\n\tabstract = {Purpose of review The aim of this study was to review recent advances and evidence for the use of cardiac output monitors to guide perioperative haemodynamic therapy. Recent findings There are multiple different cardiac output monitoring devices available for clinical use which are coupled with many different intervention protocols to manipulate perioperative haemodynamics. There is little evidence to demonstrate superiority of any one device. Previous small studies and meta-analyses have suggested that perioperative haemodynamic therapy guided by cardiac output monitoring improves outcomes after major surgery. Despite relatively low-quality evidence several national bodies have recommended ‘perioperative goal-directed therapy' (GDT) as a standard of care. Recent larger trials of GDT have mostly failed to prove a benefit of GDT and one explanation for this is the increased quality of usual care that may be occurring because of initiatives such as enhanced recovery after surgery and the WHO Safer Surgery programmes. Summary Perioperative GDT remains an exciting intervention to reduce significant morbidity following major surgery; however, it is not yet a proven standard of care. Further large pragmatic trials are required to demonstrate its effectiveness particularly in the era of enhanced recovery after surgery programmes.},\n\tnumber = {4},\n\tjournal = {Current Opinion in Critical Care},\n\tauthor = {McGuinness, Shay and Parke, Rachael},\n\tyear = {2015},\n\tnote = {Number: 4},\n\tkeywords = {cardiac output monitoring, goal directed therapy, haemodynamic optimization, perioperative care},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Upper extremity deep vein thrombosis in a TV cameraman.\n \n \n \n\n\n \n Beasley, R.; Braithwaite, I.; and Evans, R\n\n\n \n\n\n\n Occupational medicine (Oxford, England), 65. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_upper_2015,\n\ttitle = {Upper extremity deep vein thrombosis in a {TV} cameraman},\n\tvolume = {65},\n\tdoi = {10.1093/occmed/kqu212},\n\tjournal = {Occupational medicine (Oxford, England)},\n\tauthor = {Beasley, Richard and Braithwaite, Irene and Evans, R},\n\tyear = {2015},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.\n \n \n \n\n\n \n Fingleton, J.; Travers, J.; Williams, M.; Charles, T.; Bowles, D.; Strik, R.; Shirtcliffe, P.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Journal of Allergy and Clinical Immunology, 136. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{fingleton_treatment_2015,\n\ttitle = {Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults},\n\tvolume = {136},\n\tdoi = {10.1016/j.jaci.2015.01.013},\n\tjournal = {Journal of Allergy and Clinical Immunology},\n\tauthor = {Fingleton, James and Travers, Justin and Williams, Mathew and Charles, Thomas and Bowles, Darren and Strik, Rianne and Shirtcliffe, Philippa and Weatherall, Mark and Beasley, Richard},\n\tyear = {2015},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Three-month validation of a turbuhaler electronic monitoring device: Implications for asthma clinical trial use.\n \n \n \n\n\n \n Pilcher, J.; Shirtcliffe, P.; Patel, M.; McKinstry, S.; Cripps, T.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open Respiratory Research, 2: e000097. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{pilcher_three-month_2015,\n\ttitle = {Three-month validation of a turbuhaler electronic monitoring device: {Implications} for asthma clinical trial use},\n\tvolume = {2},\n\tdoi = {10.1136/bmjresp-2015-000097},\n\tjournal = {BMJ Open Respiratory Research},\n\tauthor = {Pilcher, Janine and Shirtcliffe, Philippa and Patel, Mitesh and McKinstry, Steve and Cripps, Terrianne and Weatherall, Mark and Beasley, Richard},\n\tyear = {2015},\n\tpages = {e000097},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: ‘Swimming between the flags'.\n \n \n \n\n\n \n Beasley, R.; Chien, J.; Douglas, J.; Eastlake, L.; Farah, C.; King, G.; Moore, R.; Pilcher, J.; Richards, M.; Smith, S.; and Walters, H.\n\n\n \n\n\n\n Respirology, 20: 1182–1191. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_thoracic_2015,\n\ttitle = {Thoracic {Society} of {Australia} and {New} {Zealand} oxygen guidelines for acute oxygen use in adults: ‘{Swimming} between the flags'},\n\tvolume = {20},\n\tdoi = {10.1111/resp.12620},\n\tjournal = {Respirology},\n\tauthor = {Beasley, Richard and Chien, Jimmy and Douglas, James and Eastlake, Leonie and Farah, Claude and King, Gregory and Moore, Rosemary and Pilcher, Janine and Richards, Michael and Smith, Sheree and Walters, Haydn},\n\tyear = {2015},\n\tpages = {1182--1191},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n The effect of 1 g of acetaminophen twice daily for 12 weeks on alanine transaminase levels—A randomized placebo-controlled trial.\n \n \n \n\n\n \n Ioannides, S.; Siebers, R.; Perrin, K.; Weatherall, M.; Crane, J.; Travers, J.; Shirtcliffe, P.; and Beasley, R.\n\n\n \n\n\n\n Clinical biochemistry, 48. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{ioannides_effect_2015,\n\ttitle = {The effect of 1 g of acetaminophen twice daily for 12 weeks on alanine transaminase levels—{A} randomized placebo-controlled trial},\n\tvolume = {48},\n\tdoi = {10.1016/j.clinbiochem.2015.04.011},\n\tjournal = {Clinical biochemistry},\n\tauthor = {Ioannides, Sally and Siebers, Robert and Perrin, Kyle and Weatherall, Mark and Crane, Julian and Travers, Justin and Shirtcliffe, Philippa and Beasley, Richard},\n\tyear = {2015},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Supplemental parenteral nutrition in critically ill patients: a study protocol for a phase II randomised controlled trial.\n \n \n \n\n\n \n Ridley, E. J; Davies, A. R; Parke, R.; Bailey, M.; McArthur, C.; Gillanders, L.; Cooper, D. J; and McGuinness, S.\n\n\n \n\n\n\n Trials, 16(1): 587. 2015.\n Number: 1 Publisher: BioMed Central\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{ridley_supplemental_2015,\n\ttitle = {Supplemental parenteral nutrition in critically ill patients: a study protocol for a phase {II} randomised controlled trial},\n\tvolume = {16},\n\tissn = {1745-6215},\n\tnumber = {1},\n\tjournal = {Trials},\n\tauthor = {Ridley, Emma J and Davies, Andrew R and Parke, Rachael and Bailey, Michael and McArthur, Colin and Gillanders, Lyn and Cooper, David J and McGuinness, Shay},\n\tyear = {2015},\n\tnote = {Number: 1\nPublisher: BioMed Central},\n\tpages = {587},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries.\n \n \n \n \n\n\n \n KRAG, M; PERNER, A; WETTERSLEV, J; WISE, M P; BORTHWICK, M; BENDEL, S; MCARTHUR, C; COOK, D; NIELSEN, N; PELOSI, P; KEUS, F; GUTTORMSEN, A B; MOLLER, A D; MØLLER, M H; and Collaborators, t. S.\n\n\n \n\n\n\n Acta Anaesthesiologica Scandinavica, 59(5): 576–585. May 2015.\n Number: 5 Publisher: John Wiley & Sons, Ltd (10.1111)\n\n\n\n
\n\n\n\n \n \n $\"Stress$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{krag_stress_2015,\n\ttitle = {Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries},\n\tvolume = {59},\n\tissn = {0001-5172},\n\turl = {https://doi.org/10.1111/aas.12508},\n\tdoi = {10.1111/aas.12508},\n\tabstract = {Background Stress ulcer prophylaxis (SUP) may decrease the incidence of gastrointestinal bleeding in patients in the intensive care unit (ICU), but the risk of infection may be increased. In this study, we aimed to describe SUP practices in adult ICUs. We hypothesised that patient selection for SUP varies both within and between countries. Methods Adult ICUs were invited to participate in the survey. We registered country, type of hospital, type and size of ICU, preferred SUP agent, presence of local guideline, reported indications for SUP, criteria for discontinuing SUP, and concerns about adverse effects. Fisher's exact test was used to assess differences between groups. Results Ninety-seven adult ICUs in 11 countries participated (eight European). All but one ICU used SUP, and 64\\% (62/97) reported having a guideline for the use of SUP. Proton pump inhibitors were the most common SUP agent, used in 66\\% of ICUs (64/97), and H2-receptor antagonists were used 31\\% (30/97) of the units. Twenty-three different indications for SUP were reported, the most frequent being mechanical ventilation. All patients were prescribed SUP in 26\\% (25/97) of the ICUs. Adequate enteral feeding was the most frequent reason for discontinuing SUP, but 19\\% (18/97) continued SUP upon ICU discharge. The majority expressed concern about nosocomial pneumonia and Clostridium difficile infection with the use of SUP. Conclusions In this international survey, most participating ICUs reported using SUP, primarily proton pump inhibitors, but many did not have a guideline; indications varied considerably and concern existed about infectious complications.},\n\tnumber = {5},\n\tjournal = {Acta Anaesthesiologica Scandinavica},\n\tauthor = {KRAG, M and PERNER, A and WETTERSLEV, J and WISE, M P and BORTHWICK, M and BENDEL, S and MCARTHUR, C and COOK, D and NIELSEN, N and PELOSI, P and KEUS, F and GUTTORMSEN, A B and MOLLER, A D and MØLLER, M H and Collaborators, the SUP-ICU},\n\tmonth = may,\n\tyear = {2015},\n\tnote = {Number: 5\nPublisher: John Wiley \\& Sons, Ltd (10.1111)},\n\tpages = {576--585},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Siblings, asthma, rhinoconjunctivitis and eczema: a worldwide perspective from the International Study of Asthma and Allergies in Childhood.\n \n \n \n\n\n \n Strachan, D P; Aït‐Khaled, N; Foliaki, S; Mallol, J; Odhiambo, J; Pearce, N; Williams, H C; and Group, I. P. T. S.\n\n\n \n\n\n\n Clinical & Experimental Allergy, 45(1): 126–136. 2015.\n Number: 1 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{strachan_siblings_2015,\n\ttitle = {Siblings, asthma, rhinoconjunctivitis and eczema: a worldwide perspective from the {International} {Study} of {Asthma} and {Allergies} in {Childhood}},\n\tvolume = {45},\n\tissn = {0954-7894},\n\tnumber = {1},\n\tjournal = {Clinical \\& Experimental Allergy},\n\tauthor = {Strachan, D P and Aït‐Khaled, N and Foliaki, S and Mallol, J and Odhiambo, J and Pearce, N and Williams, H C and Group, ISAAC Phase Three Study},\n\tyear = {2015},\n\tnote = {Number: 1\nPublisher: Wiley Online Library},\n\tpages = {126--136},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Risk factors for asthma: Is prevention possible?.\n \n \n \n\n\n \n Beasley, R.; Semprini, A.; and Mitchell, E.\n\n\n \n\n\n\n Lancet (London, England), 386: 1075–1085. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_risk_2015,\n\ttitle = {Risk factors for asthma: {Is} prevention possible?},\n\tvolume = {386},\n\tdoi = {10.1016/S0140-6736(15)00156-7},\n\tjournal = {Lancet (London, England)},\n\tauthor = {Beasley, Richard and Semprini, Alex and Mitchell, Edwin},\n\tyear = {2015},\n\tpages = {1075--1085},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Randomized controlled trial of asthma risk with paracetamol use in infancy–a feasibility study.\n \n \n \n\n\n \n Riley, J; Braithwaite, I; Shirtcliffe, P; Caswell‐Smith, R; Hunt, A; Bowden, V; Power, S; Stanley, T; Crane, J; and Ingham, T\n\n\n \n\n\n\n Clinical & Experimental Allergy, 45(2): 448–456. 2015.\n Number: 2 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{riley_randomized_2015,\n\ttitle = {Randomized controlled trial of asthma risk with paracetamol use in infancy–a feasibility study},\n\tvolume = {45},\n\tissn = {0954-7894},\n\tnumber = {2},\n\tjournal = {Clinical \\& Experimental Allergy},\n\tauthor = {Riley, J and Braithwaite, I and Shirtcliffe, P and Caswell‐Smith, R and Hunt, A and Bowden, V and Power, S and Stanley, T and Crane, J and Ingham, T},\n\tyear = {2015},\n\tnote = {Number: 2\nPublisher: Wiley Online Library},\n\tpages = {448--456},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients.\n \n \n \n\n\n \n Krag, M.; Perner, A.; Wetterslev, J.; Wise, M. P; Borthwick, M.; Bendel, S.; McArthur, C.; Cook, D.; Nielsen, N.; and Pelosi, P.\n\n\n \n\n\n\n Intensive care medicine, 41(5): 833–845. 2015.\n Number: 5 Publisher: Springer\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{krag_prevalence_2015,\n\ttitle = {Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients},\n\tvolume = {41},\n\tissn = {0342-4642},\n\tnumber = {5},\n\tjournal = {Intensive care medicine},\n\tauthor = {Krag, Mette and Perner, Anders and Wetterslev, Jørn and Wise, Matt P and Borthwick, Mark and Bendel, Stepani and McArthur, Colin and Cook, Deborah and Nielsen, Niklas and Pelosi, Paolo},\n\tyear = {2015},\n\tnote = {Number: 5\nPublisher: Springer},\n\tpages = {833--845},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Permissive Underfeeding or Standard Enteral Feeding in Critical Illness.\n \n \n \n \n\n\n \n Peake, S; Young, P. J.; Chapman, M; and TARGET Investigators\n\n\n \n\n\n\n New England Journal of Medicine, 373(12): 1173–1176. September 2015.\n Number: 12 Publisher: Massachusetts Medical Society\n\n\n\n
\n\n\n\n \n \n $\"Permissive$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{peake_permissive_2015,\n\ttitle = {Permissive {Underfeeding} or {Standard} {Enteral} {Feeding} in {Critical} {Illness}},\n\tvolume = {373},\n\tissn = {0028-4793},\n\turl = {https://doi.org/10.1056/NEJMc1509259},\n\tdoi = {10.1056/NEJMc1509259},\n\tnumber = {12},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Peake, S and Young, Paul J. and Chapman, M and {TARGET Investigators}},\n\tmonth = sep,\n\tyear = {2015},\n\tnote = {Number: 12\nPublisher: Massachusetts Medical Society},\n\tpages = {1173--1176},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Oxygenation targets and monitoring in the critically ill: a point prevalence study of clinical practice in australia and New Zealand.\n \n \n \n\n\n \n Young, P. J; Beasley, R. W; Capellier, G.; Eastwood, G. M; and Webb, S. A R\n\n\n \n\n\n\n Critical Care and Resuscitation, 17(3): 202. 2015.\n Number: 3 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_oxygenation_2015,\n\ttitle = {Oxygenation targets and monitoring in the critically ill: a point prevalence study of clinical practice in australia and {New} {Zealand}},\n\tvolume = {17},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Young, Paul J and Beasley, Richard W and Capellier, Gilles and Eastwood, Glenn M and Webb, Steve A R},\n\tyear = {2015},\n\tnote = {Number: 3\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {202},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease.\n \n \n \n\n\n \n Pilcher, J.; Weatherall, M.; Perrin, K.; and Beasley, R.\n\n\n \n\n\n\n Expert review of respiratory medicine, 9: 1–7. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{pilcher_oxygen_2015,\n\ttitle = {Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease},\n\tvolume = {9},\n\tdoi = {10.1586/17476348.2015.1016503},\n\tjournal = {Expert review of respiratory medicine},\n\tauthor = {Pilcher, Janine and Weatherall, Mark and Perrin, Kyle and Beasley, Richard},\n\tyear = {2015},\n\tpages = {1--7},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Overview of the study protocols and statistical analysis plan for the Saline versus Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program.\n \n \n \n\n\n \n Reddy, S. K; Young, P. J; Beasley, R. W; Mackle, D. M; McGuinness, S. P; McArthur, C. J; Henderson, S. J; Weinberg, L.; French, C. J; and Orford, N. R\n\n\n \n\n\n\n Critical Care and Resuscitation, 17(1): 29. 2015.\n Number: 1 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{reddy_overview_2015,\n\ttitle = {Overview of the study protocols and statistical analysis plan for the {Saline} versus {Plasma}-{Lyte} 148 for {Intravenous} {Fluid} {Therapy} ({SPLIT}) research program},\n\tvolume = {17},\n\tnumber = {1},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Reddy, Sumeet K and Young, Paul J and Beasley, Richard W and Mackle, Diane M and McGuinness, Shay P and McArthur, Colin J and Henderson, Seton J and Weinberg, Laurence and French, Craig J and Orford, Neil R},\n\tyear = {2015},\n\tnote = {Number: 1\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {29},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Maternal post-natal tobacco use and current parental tobacco use is associated with higher body mass index in children and adolescents: An international crosssectional study.\n \n \n \n\n\n \n Braithwaite, I.; Stewart, A.; J Hancox, R.; Beasley, R.; Murphy, R.; and Mitchell, E.\n\n\n \n\n\n\n BMC pediatrics, 15: 220. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{braithwaite_maternal_2015,\n\ttitle = {Maternal post-natal tobacco use and current parental tobacco use is associated with higher body mass index in children and adolescents: {An} international crosssectional study},\n\tvolume = {15},\n\tdoi = {10.1186/s12887-015-0538-x},\n\tjournal = {BMC pediatrics},\n\tauthor = {Braithwaite, Irene and Stewart, Alistair and J Hancox, Robert and Beasley, Richard and Murphy, Rinki and Mitchell, Edwin},\n\tyear = {2015},\n\tpages = {220},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Hospital admissions for non-cystic fibrosis bronchiectasis in New Zealand.\n \n \n \n\n\n \n Bibby, S.; Milne, R.; and Beasley, R.\n\n\n \n\n\n\n The New Zealand Medical Journal (Online), 128(1421): 30. 2015.\n Number: 1421 Publisher: New Zealand Medical Association (NZMA)\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{bibby_hospital_2015,\n\ttitle = {Hospital admissions for non-cystic fibrosis bronchiectasis in {New} {Zealand}},\n\tvolume = {128},\n\tissn = {1175-8716},\n\tnumber = {1421},\n\tjournal = {The New Zealand Medical Journal (Online)},\n\tauthor = {Bibby, Susan and Milne, Richard and Beasley, Richard},\n\tyear = {2015},\n\tnote = {Number: 1421\nPublisher: New Zealand Medical Association (NZMA)},\n\tpages = {30},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Effect of Very-High-Flow Nasal Therapy on Airway Pressure and End-Expiratory Lung Impedance in Healthy Volunteers.\n \n \n \n \n\n\n \n Parke, R. L; Bloch, A.; and McGuinness, S. P\n\n\n \n\n\n\n Respiratory Care, 60(10): 1397 LP – 1403. October 2015.\n Number: 10\n\n\n\n
\n\n\n\n \n \n $\"Effect$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{parke_effect_2015,\n\ttitle = {Effect of {Very}-{High}-{Flow} {Nasal} {Therapy} on {Airway} {Pressure} and {End}-{Expiratory} {Lung} {Impedance} in {Healthy} {Volunteers}},\n\tvolume = {60},\n\turl = {http://rc.rcjournal.com/content/60/10/1397.abstract},\n\tdoi = {10.4187/respcare.04028},\n\tabstract = {BACKGROUND: Previous research has demonstrated a positive linear correlation between flow delivered and airway pressure generated by high-flow nasal therapy. Current practice is to use flows over a range of 30–60 L/min; however, it is technically possible to apply higher flows. In this study, airway pressure measurements and electrical impedance tomography were used to assess the relationship between flows of up to 100 L/min and changes in lung physiology.METHODS: Fifteen healthy volunteers were enrolled into this study. A high-flow nasal system capable of delivering a flow of 100 L/min was purpose-built using 2 Optiflow systems. Airway pressure was measured via the nasopharynx, and cumulative changes in end-expiratory lung impedance were recorded using the PulmoVista 500 system at gas flows of 30–100 L/min in increments of 10 L/min.RESULTS: The mean age of study participants was 31 (range 22–44) y, the mean ± SD height was 171.8 ± 7.5 cm, the mean ± SD weight was 69.7 ± 10 kg, and 47\\% were males. Flows ranged from 30 to 100 L/min with resulting mean ± SD airway pressures of 2.7 ± 0.7 to 11.9 ± 2.7 cm H2O. A cumulative and linear increase in end-expiratory lung impedance was observed with increasing flows, as well as a decrease in breathing frequency.CONCLUSIONS: Measured airway pressure and lung impedance increased linearly with increased gas flow. Observed airway pressures were in the range used clinically with face-mask noninvasive ventilation. Developments in delivery systems may result in this therapy being an acceptable alternative to face-mask noninvasive ventilation.},\n\tnumber = {10},\n\tjournal = {Respiratory Care},\n\tauthor = {Parke, Rachael L and Bloch, Andreas and McGuinness, Shay P},\n\tmonth = oct,\n\tyear = {2015},\n\tnote = {Number: 10},\n\tpages = {1397 LP -- 1403},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Hospital admissions for chronic obstructive pulmonary disease in New Zealand.\n \n \n \n\n\n \n Milne, R.; and Beasley, R.\n\n\n \n\n\n\n . 2015.\n Publisher: New Zealand Medical Association\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{milne_hospital_2015,\n\ttitle = {Hospital admissions for chronic obstructive pulmonary disease in {New} {Zealand}},\n\tissn = {0028-8446},\n\tauthor = {Milne, Richard and Beasley, Richard},\n\tyear = {2015},\n\tnote = {Publisher: New Zealand Medical Association},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Fluid administration, vasopressor use and patient outcomes in a group of high-risk cardiac surgical patients receiving postoperative goal-directed haemodynamic therapy: a pilot study.\n \n \n \n\n\n \n Walker, L J C; and Young, P J\n\n\n \n\n\n\n Anaesthesia and intensive care, 43(5): 617–627. 2015.\n Number: 5 Publisher: SAGE Publications Sage UK: London, England\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{walker_fluid_2015,\n\ttitle = {Fluid administration, vasopressor use and patient outcomes in a group of high-risk cardiac surgical patients receiving postoperative goal-directed haemodynamic therapy: a pilot study},\n\tvolume = {43},\n\tissn = {0310-057X},\n\tnumber = {5},\n\tjournal = {Anaesthesia and intensive care},\n\tauthor = {Walker, L J C and Young, P J},\n\tyear = {2015},\n\tnote = {Number: 5\nPublisher: SAGE Publications Sage UK: London, England},\n\tpages = {617--627},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.\n \n \n \n \n\n\n \n Beasley, R. W; Donohue, J. F; Mehta, R.; Nelson, H. S; Clay, M.; Moton, A.; Kim, H.; and Hederer, B. M\n\n\n \n\n\n\n BMJ Open, 5(2): e006131. February 2015.\n Number: 2\n\n\n\n
\n\n\n\n \n \n $\"Effect$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_effect_2015,\n\ttitle = {Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial},\n\tvolume = {5},\n\turl = {http://bmjopen.bmj.com/content/5/2/e006131.abstract},\n\tdoi = {10.1136/bmjopen-2014-006131},\n\tabstract = {Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations. Setting 174 research centres in nine countries. Participants 1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis. Intervention Patients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6–21 months. Primary and secondary outcome measures The primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids. Results Treatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3\\%) vs 6 events (0.8\\%); difference −0.52 percentage point; 95\\% CI −1.25 to 0.21, p=0.160, HR=0.31; 95\\% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95\\% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0\\% in the QMF149 group and 73.4\\% in the MF group). Serious adverse events occurred in 4\\% and 5.8\\% of patients in the QMF149 and MF groups, respectively. Conclusions No significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma. Trial registration number ClinicalTrials.gov; NCT00941798.},\n\tnumber = {2},\n\tjournal = {BMJ Open},\n\tauthor = {Beasley, Richard W and Donohue, James F and Mehta, Rajendra and Nelson, Harold S and Clay, Michelle and Moton, Allen and Kim, Han-Joo and Hederer, Bettina M},\n\tmonth = feb,\n\tyear = {2015},\n\tnote = {Number: 2},\n\tpages = {e006131},\n}\n\n

\n

\n\n\n

\n Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations. Setting 174 research centres in nine countries. Participants 1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis. Intervention Patients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6–21 months. Primary and secondary outcome measures The primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids. Results Treatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3%) vs 6 events (0.8%); difference −0.52 percentage point; 95% CI −1.25 to 0.21, p=0.160, HR=0.31; 95% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0% in the QMF149 group and 73.4% in the MF group). Serious adverse events occurred in 4% and 5.8% of patients in the QMF149 and MF groups, respectively. Conclusions No significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma. Trial registration number ClinicalTrials.gov; NCT00941798.\n

\n\n\n

\n \n\n \n \n \n \n \n Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial.\n \n \n \n\n\n \n Young, P.; Bailey, M.; Beasley, R.; Henderson, S.; Mackle, D.; McArthur, C.; Mcguinness, S.; Mehrtens, J.; Myburgh, J.; Psirides, A.; Reddy, S.; and Bellomo, R.\n\n\n \n\n\n\n JAMA, 314: 1–10. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_effect_2015-1,\n\ttitle = {Effect of a {Buffered} {Crystalloid} {Solution} vs {Saline} on {Acute} {Kidney} {Injury} {Among} {Patients} in the {Intensive} {Care} {Unit}: {The} {SPLIT} {Randomized} {Clinical} {Trial}},\n\tvolume = {314},\n\tdoi = {10.1001/jama.2015.12334},\n\tjournal = {JAMA},\n\tauthor = {Young, Paul and Bailey, Michael and Beasley, Richard and Henderson, Seton and Mackle, Diane and McArthur, Colin and Mcguinness, Shay and Mehrtens, Jan and Myburgh, John and Psirides, Alex and Reddy, Sumeet and Bellomo, Rinaldo},\n\tyear = {2015},\n\tpages = {1--10},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Early temperature and mortality in critically ill patients with acute neurological diseases: trauma and stroke differ from infection.\n \n \n \n\n\n \n Saxena, M.; Young, P.; Pilcher, D.; Bailey, M.; Harrison, D.; Bellomo, R.; Finfer, S.; Beasley, R.; Hyam, J.; Menon, D.; Rowan, K.; and Myburgh, J.\n\n\n \n\n\n\n Intensive care medicine, 41. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{saxena_early_2015,\n\ttitle = {Early temperature and mortality in critically ill patients with acute neurological diseases: trauma and stroke differ from infection},\n\tvolume = {41},\n\tdoi = {10.1007/s00134-015-3676-6},\n\tjournal = {Intensive care medicine},\n\tauthor = {Saxena, Manoj and Young, Paul and Pilcher, David and Bailey, Michael and Harrison, David and Bellomo, Rinaldo and Finfer, Simon and Beasley, Richard and Hyam, Jonathan and Menon, David and Rowan, Kathryn and Myburgh, John},\n\tyear = {2015},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Early mobilization and recovery in mechanically ventilated patients in the ICU: a bi-national, multi-centre, prospective cohort study.\n \n \n \n \n\n\n \n The TEAM Study Investigators\n\n\n \n\n\n\n Critical Care, 19(1): 81. 2015.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"Early$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{the_team_study_investigators_early_2015,\n\ttitle = {Early mobilization and recovery in mechanically ventilated patients in the {ICU}: a bi-national, multi-centre, prospective cohort study},\n\tvolume = {19},\n\tissn = {1364-8535},\n\turl = {https://doi.org/10.1186/s13054-015-0765-4},\n\tdoi = {10.1186/s13054-015-0765-4},\n\tabstract = {The aim of this study was to investigate current mobilization practice, strength at ICU discharge and functional recovery at 6 months among mechanically ventilated ICU patients.},\n\tnumber = {1},\n\tjournal = {Critical Care},\n\tauthor = {{The TEAM Study Investigators}},\n\tyear = {2015},\n\tnote = {Number: 1},\n\tpages = {81},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Association between paracetamol use in infancy or childhood with body mass index.\n \n \n \n \n\n\n \n Murphy, R.; Stewart, A. W; Braithwaite, I.; Beasley, R.; Hancox, R. J; Mitchell, E. A; and Group, t. I. P. T. S.\n\n\n \n\n\n\n Obesity, 23(5): 1030–1038. May 2015.\n Number: 5 Publisher: John Wiley & Sons, Ltd\n\n\n\n
\n\n\n\n \n \n $\"Association$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{murphy_association_2015,\n\ttitle = {Association between paracetamol use in infancy or childhood with body mass index},\n\tvolume = {23},\n\tissn = {1930-7381},\n\turl = {https://doi.org/10.1002/oby.21045},\n\tdoi = {10.1002/oby.21045},\n\tabstract = {Objective Paracetamol has the potential to also promote weight gain by indirect activation of cannabinoid receptors. The association between paracetamol use in the first 12 months of life or recent high use and BMI in children and adolescents was investigated. Methods Paracetamol use in the first 12 months of life (reported by parents/guardians of 6- and 7-year-olds) or in the past 12 months (reported by parents/guardians of 6- and 7-year-olds or self-reported by adolescents aged 13?14) was examined in relation to BMI in a large multicentre cross-sectional study (2000?2003). Linear regression results were adjusted for whether height and weight were reported or measured, age, sex, country gross national income, study centre, maternal smoking, and recent wheeze. Results Data were available from 76,216 children (18 countries) and 188,469 adolescents (35 countries). BMI was +0.07 kg/m2 higher in children with early life paracetamol exposure, from affluent countries only. Frequent recent paracetamol use was associated with higher BMI (+0.17 kg/m2, P?{\\textbackslash}textless?0.0001) among adolescents from affluent countries only, but not in children (P?=?0.41). Conclusions Paracetamol may be causally related to increased BMI; alternatively, the association may be explained by lifestyle or other factors that correlate with paracetamol use in affluent countries.},\n\tnumber = {5},\n\tjournal = {Obesity},\n\tauthor = {Murphy, Rinki and Stewart, Alistair W and Braithwaite, Irene and Beasley, Richard and Hancox, Robert J and Mitchell, Edwin A and Group, the ISAAC Phase Three Study},\n\tmonth = may,\n\tyear = {2015},\n\tnote = {Number: 5\nPublisher: John Wiley \\& Sons, Ltd},\n\tpages = {1030--1038},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Association between breastfeeding and body mass index at age 6–7 years in an international survey.\n \n \n \n \n\n\n \n Hancox, R J; Stewart, A W; Braithwaite, I; Beasley, R; Murphy, R; Mitchell, E A; and Group, I. P. T. S.\n\n\n \n\n\n\n Pediatric Obesity, 10(4): 283–287. August 2015.\n Number: 4 Publisher: John Wiley & Sons, Ltd (10.1111)\n\n\n\n
\n\n\n\n \n \n $\"Association$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{hancox_association_2015,\n\ttitle = {Association between breastfeeding and body mass index at age 6–7 years in an international survey},\n\tvolume = {10},\n\tissn = {2047-6302},\n\turl = {https://doi.org/10.1111/ijpo.266},\n\tdoi = {10.1111/ijpo.266},\n\tabstract = {Summary Background Breastfeeding is believed to reduce children's risk for obesity but data are conflicting. It is also uncertain if breastfeeding has different effects on obesity in high- and low-income countries. Objectives This study aimed to investigate the association between having been breastfed and body mass index (BMI) in 6- to 7-year-old children in a large international survey. Methods Parents/guardians reported whether their child had been breastfed and their current height and weight. Some centres measured height and weight directly. Analyses adjusted for whether height and weight were reported or measured, child's age, sex, country gross national income and centre. Results Data were available for 76?635 participants from 31 centres in 18 countries. Reported breastfeeding rates varied from 27 to 98\\%. After adjusting for potential confounders, the estimated BMI difference was 0.04?kg?m?2 lower among those who had been breastfed (P?=?0.07). The risk for being overweight or obese was slightly lower among breastfed children (odds ratio?=?0.95, P?=?0.012). There was no evidence that the association between breastfeeding and BMI was different in lower income countries compared with higher income countries. Conclusions The findings suggest that breastfeeding has little impact on children's BMI. Increasing breastfeeding is unlikely to reduce the global epidemic of childhood obesity.},\n\tnumber = {4},\n\tjournal = {Pediatric Obesity},\n\tauthor = {Hancox, R J and Stewart, A W and Braithwaite, I and Beasley, R and Murphy, R and Mitchell, E A and Group, ISAAC Phase Three Study},\n\tmonth = aug,\n\tyear = {2015},\n\tnote = {Number: 4\nPublisher: John Wiley \\& Sons, Ltd (10.1111)},\n\tkeywords = {Body mass index, breastfeeding, children, obesity},\n\tpages = {283--287},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.\n \n \n \n\n\n \n Young, P.; Saxena, M.; Bellomo, R.; Freebairn, R.; Hammond, N.; Van Haren, F.; Holliday, M.; Henderson, S.; Mackle, D.; McArthur, C.; Mcguinness, S.; Myburgh, J.; Weatherall, M.; Webb, S.; and Beasley, R.\n\n\n \n\n\n\n The New England journal of medicine, 373. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_acetaminophen_2015-1,\n\ttitle = {Acetaminophen for {Fever} in {Critically} {Ill} {Patients} with {Suspected} {Infection}},\n\tvolume = {373},\n\tdoi = {10.1056/NEJMoa1508375},\n\tjournal = {The New England journal of medicine},\n\tauthor = {Young, Paul and Saxena, Manoj and Bellomo, Rinaldo and Freebairn, Ross and Hammond, Naomi and Van Haren, Frank and Holliday, Mark and Henderson, Seton and Mackle, Diane and McArthur, Colin and Mcguinness, Shay and Myburgh, John and Weatherall, Mark and Webb, Steve and Beasley, Richard},\n\tyear = {2015},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n ARTICLE The use of β 2 -agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis.\n \n \n \n\n\n \n Patel, M.; Pilcher, J.; J Hancox, R.; Sheahan, D.; Pritchard, A.; Braithwaite, I.; Shaw, D.; Black, P.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Primary Care Respiratory Journal, 2599. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{patel_article_2015,\n\ttitle = {{ARTICLE} {The} use of β 2 -agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis},\n\tvolume = {2599},\n\tdoi = {10.1038/npjpcrm.2014.99},\n\tjournal = {Primary Care Respiratory Journal},\n\tauthor = {Patel, Mitesh and Pilcher, Janine and J Hancox, Robert and Sheahan, Davitt and Pritchard, Alison and Braithwaite, Irene and Shaw, Dominick and Black, Peter and Weatherall, Mark and Beasley, Richard},\n\tyear = {2015},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Acute use of oxygen therapy.\n \n \n \n\n\n \n Pilcher, J.; and Beasley, R.\n\n\n \n\n\n\n Australian prescriber, 38(3): 98. 2015.\n Number: 3 Publisher: Citeseer\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{pilcher_acute_2015,\n\ttitle = {Acute use of oxygen therapy},\n\tvolume = {38},\n\tnumber = {3},\n\tjournal = {Australian prescriber},\n\tauthor = {Pilcher, Janine and Beasley, Richard},\n\tyear = {2015},\n\tnote = {Number: 3\nPublisher: Citeseer},\n\tpages = {98},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n A Randomised feasibility study to assess a novel strategy to rationalise fluid in patients after cardiac surgery.\n \n \n \n \n\n\n \n Parke, R L; McGuinness, S P; Gilder, E; McCarthy, L W; and Cowdrey, K. L\n\n\n \n\n\n\n British Journal of Anaesthesia, 115(1): 45–52. 2015.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"A$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{parke_randomised_2015,\n\ttitle = {A {Randomised} feasibility study to assess a novel strategy to rationalise fluid in patients after cardiac surgery},\n\tvolume = {115},\n\tissn = {0007-0912},\n\turl = {http://www.sciencedirect.com/science/article/pii/S0007091217312394},\n\tdoi = {https://doi.org/10.1093/bja/aev118},\n\tabstract = {Background After cardiac surgery, patients receive large amounts of fluid in the Intensive Care Unit (ICU). We plan to conduct a multi-centre randomised controlled trial, of a conservative fluid regime, in patients after cardiac surgery, and have reported results of a feasibility study that evaluated efficacy and safety of the proposed regime. Methods After ethical approval, a single-centre, prospectively randomised interventional study was undertaken. Participants were randomised to either usual care, or to a protocolised algorithm, utilising stroke volume variation, to guide fluid administration to patients who were deemed to have inadequate cardiac output and were likely to be volume responsive. The study protocol lasted from ICU admission to de-sedation or 24 h, whichever occurred first. Results We randomised 144 subjects over 9 months. Less bolus fluid and less total overall fluid volume was administered in the intervention group (median (IQR) 1620 ml (500–3410) and 2525 ml (1440–5250; P{\\textbackslash}textless0.001), compared with the usual care group (2050 ml (910–4280) and 2980 ml (2070–6580; P=0.001), from ICU admission to extubation. There was no significant difference in incidence of acute kidney injury or the average amount of fluid administered to the usual care group at the beginning compared with the end of the study. Conclusion It is both possible and safe to achieve a significant reduction in the amount of fluid administered to patients, allocated to a conservative fluid protocol. These results suggest that a planned multi-centre study is both justified and feasible. Clinical trial registration Australia New Zealand Clinical Trials Registry www.anzctr.org.au (ACTRN12612000754842).},\n\tnumber = {1},\n\tjournal = {British Journal of Anaesthesia},\n\tauthor = {Parke, R L and McGuinness, S P and Gilder, E and McCarthy, L W and Cowdrey, K.-A. L},\n\tyear = {2015},\n\tnote = {Number: 1},\n\tkeywords = {acute kidney injury, cardiac output, cardiac surgery, haemodynamics, intensive care units},\n\tpages = {45--52},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n A multicentre audit of temperature patterns after traumatic brain injury.\n \n \n \n\n\n \n Saxena, M. K; Taylor, C.; Hammond, N.; Young, P.; Mysore, J.; Billot, L.; Myburgh, A.; and Myburgh, J.\n\n\n \n\n\n\n Critical Care and Resuscitation, 17(2): 129. 2015.\n Number: 2 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{saxena_multicentre_2015,\n\ttitle = {A multicentre audit of temperature patterns after traumatic brain injury},\n\tvolume = {17},\n\tnumber = {2},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Saxena, Manoj K and Taylor, Colman and Hammond, Naomi and Young, Paul and Mysore, Jayanthi and Billot, Laurent and Myburgh, Ashleigh and Myburgh, John},\n\tyear = {2015},\n\tnote = {Number: 2\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {129},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.\n \n \n \n \n\n\n \n Dulhunty, J. M; Roberts, J. A; Davis, J. S; Webb, S. A R; Bellomo, R.; Gomersall, C.; Shirwadkar, C.; Eastwood, G. M; Myburgh, J.; Paterson, D. L; Starr, T.; Paul, S. K; and Lipman, J.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 192(11): 1298–1305. July 2015.\n Number: 11 Publisher: American Thoracic Society - AJRCCM\n\n\n\n
\n\n\n\n \n \n $\"A$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{dulhunty_multicenter_2015,\n\ttitle = {A {Multicenter} {Randomized} {Trial} of {Continuous} versus {Intermittent} β-{Lactam} {Infusion} in {Severe} {Sepsis}},\n\tvolume = {192},\n\tissn = {1073-449X},\n\turl = {https://doi.org/10.1164/rccm.201505-0857OC},\n\tdoi = {10.1164/rccm.201505-0857OC},\n\tabstract = {Rationale: Continuous infusion of ?-lactam antibiotics may improve outcomes because of time-dependent antibacterial activity compared with intermittent dosing.Objectives: To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis.Methods: We conducted a randomized controlled trial in 25 intensive care units (ICUs). Participants commenced on piperacillin?tazobactam, ticarcillin?clavulanate, or meropenem were randomized to receive the prescribed antibiotic via continuous or 30-minute intermittent infusion for the remainder of the treatment course or until ICU discharge. The primary outcome was the number of alive ICU-free days at Day 28. Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive organ failure?free days at Day 14, and duration of bacteremia.Measurements and Main Results: We enrolled 432 eligible participants with a median age of 64 years and an Acute Physiology and Chronic Health Evaluation II score of 20. There was no difference in ICU-free days: 18 days (interquartile range, 2?24) and 20 days (interquartile range, 3?24) in the continuous and intermittent groups (P?=?0.38). There was no difference in 90-day survival: 74.3\\% (156 of 210) and 72.5\\% (158 of 218); hazard ratio, 0.91 (95\\% confidence interval, 0.63?1.31; P?=?0.61). Clinical cure was 52.4\\% (111 of 212) and 49.5\\% (109 of 220); odds ratio, 1.12 (95\\% confidence interval, 0.77?1.63; P?=?0.56). There was no difference in organ failure?free days (6 d; P?=?0.27) and duration of bacteremia (0 d; P?=?0.24).Conclusions: In critically ill patients with severe sepsis, there was no difference in outcomes between ?-lactam antibiotic administration by continuous and intermittent infusion.Australian New Zealand Clinical Trials Registry number (ACT RN12612000138886).},\n\tnumber = {11},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Dulhunty, Joel M and Roberts, Jason A and Davis, Joshua S and Webb, Steven A R and Bellomo, Rinaldo and Gomersall, Charles and Shirwadkar, Charudatt and Eastwood, Glenn M and Myburgh, John and Paterson, David L and Starr, Therese and Paul, Sanjoy K and Lipman, Jeffrey},\n\tmonth = jul,\n\tyear = {2015},\n\tnote = {Number: 11\nPublisher: American Thoracic Society - AJRCCM},\n\tpages = {1298--1305},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n A topical Kanuka honey formulation is an effective treatment for rosacea.\n \n \n \n\n\n \n Holt, S; Beasley, R.; Weatherall, M.; Braithwaite, I.; Holliday, M.; Montgomery, B; Corin, A; Helm, C; Sheahan, D.; and Tofield, C.\n\n\n \n\n\n\n Australasian Journal of Dermatology, 56: A5–A6. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{holt_topical_2015,\n\ttitle = {A topical {Kanuka} honey formulation is an effective treatment for rosacea},\n\tvolume = {56},\n\tjournal = {Australasian Journal of Dermatology},\n\tauthor = {Holt, S and Beasley, Richard and Weatherall, Mark and Braithwaite, Irene and Holliday, Mark and Montgomery, B and Corin, A and Helm, C and Sheahan, Davitt and Tofield, Christopher},\n\tyear = {2015},\n\tpages = {A5--A6},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Randomised controlled trial of topical kanuka honey for the treatment of rosacea.\n \n \n \n\n\n \n Braithwaite, I.; Hunt, A.; Riley, J.; Fingleton, J.; Kocks, J.; Corin, A.; Helm, C.; Sheahan, D.; Tofield, C.; Montgomery, B.; Holliday, M.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ open, 5: e007651. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{braithwaite_randomised_2015,\n\ttitle = {Randomised controlled trial of topical kanuka honey for the treatment of rosacea},\n\tvolume = {5},\n\tdoi = {10.1136/bmjopen-2015-007651},\n\tjournal = {BMJ open},\n\tauthor = {Braithwaite, Irene and Hunt, Anna and Riley, Judith and Fingleton, James and Kocks, Janwillem and Corin, Andrew and Helm, Colin and Sheahan, Davitt and Tofield, Christopher and Montgomery, Barney and Holliday, Mark and Weatherall, Mark and Beasley, Richard},\n\tyear = {2015},\n\tpages = {e007651},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n A single‐blind randomised controlled trial of topical kanuka honey for the treatment of nappy rash.\n \n \n \n\n\n \n Semprini, A.; Fingleton, J.; Hunt, A.; Riley, J.; Corin, A.; and Tofield, C.\n\n\n \n\n\n\n Focus on Alternative and Complementary Therapies, 20(3-4): 187–188. 2015.\n Number: 3-4 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{semprini_singleblind_2015,\n\ttitle = {A single‐blind randomised controlled trial of topical kanuka honey for the treatment of nappy rash},\n\tvolume = {20},\n\tissn = {1465-3753},\n\tnumber = {3-4},\n\tjournal = {Focus on Alternative and Complementary Therapies},\n\tauthor = {Semprini, Alex and Fingleton, James and Hunt, Anna and Riley, Judith and Corin, Andrew and Tofield, Christopher},\n\tyear = {2015},\n\tnote = {Number: 3-4\nPublisher: Wiley Online Library},\n\tpages = {187--188},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n A single-blind randomised controlled trial of a topical kanuka honey formulation for the treatment of acne.\n \n \n \n\n\n \n Holt, S; Beasley, R.; Weatherall, M.; Braithwaite, I.; Holliday, M.; Montgomery, B; Corin, A; Helm, C; Sheahan, D.; and Tofield, C.\n\n\n \n\n\n\n Australasian Journal of Dermatology, 56: A5–A5. 2015.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{holt_single-blind_2015,\n\ttitle = {A single-blind randomised controlled trial of a topical kanuka honey formulation for the treatment of acne},\n\tvolume = {56},\n\tjournal = {Australasian Journal of Dermatology},\n\tauthor = {Holt, S and Beasley, Richard and Weatherall, Mark and Braithwaite, Irene and Holliday, Mark and Montgomery, B and Corin, A and Helm, C and Sheahan, Davitt and Tofield, Christopher},\n\tyear = {2015},\n\tpages = {A5--A5},\n}\n

\n

\n\n\n\n